Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 88.72$. Average daily volumn in 3 months 2.59M. Market cap 202.36B



Stock symbol : NVS. Exchange : NYSE. Currency : USD
Lastest price : 91.46$. Total volume : 2.16M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Novartis AG (NVS)
Last Price
91.46$
Change
0.20
Volume
2.16M

Previous Close91.26
Open91.02
Day Range90.59-91.47
Bid91.35 x 900
Ask91.82 x 1k
Volume2.16M
Average Volume2.59M
Market Cap202.36B
Beta0.51
52 Week Range79.09-95.17
Trailing P/E8.52
Foward P/E13.41
Dividend (Yield %)3.64%
Ex-Dividend Date2022-03-08



Financial Details


According to Novartis AG's financial reports the company's revenue in 2021 were 52.88B an increase( +6.12%) over the years 2020 revenue that were of 49.9B. In 2021 the company's total earnings were 24.02B while total earnings in 2020 were 8.07B( +200%).


Loading ...



Organization

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Market Cap:
202.36B
Revenue:
52.88B
Total Assets:
131.79B
Total Cash:
12.41B


News about "Novartis AG"

Novartis Pharma AG: FDA approves Novartis Kymriah CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

Source from : Finanznachrichten - 21 hours ago

Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah ...See details»


novartis-ag-nvs-these-numbers-are-too-good-to-be-true-image

Novartis AG (NVS): These Numbers are Too Good to be true

Source from : investchronicle - 10 days ago

For the readers interested in the stock health of Novartis AG (NVS). It is currently valued at $87.94. When the transactions were called off in the previous session, Stock hit the highs of $88.23, ...See details»


Is Novartis AGโ€™s (NYSE: NVS) Stock A Good Medium-Term Investment?

Source from : stocksregister - 4 days ago

Novartis AG (NYSE:NVS) price is hovering higher on Tuesday, May 24, jumping 0.76% above its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at todayโ€™s pr ...See details»


Novartis AG: Novartisโ€™ Q1 Slightly Below Our Expectations, but Outlook Is Steady and Shares Appear Fairly Valued

Source from : YAHOO!Finance - 26 days ago

Find the latest Novartis AG (NVS) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»


Riding the Trend or Protecting Profits | Novartis AG (NVS)

Source from : newsheater - 9 days ago

Novartis AG (NYSE:NVS) went down by -0.27% from its latest closing price compared to the recent 1-year high of $95.17. The companyโ€™s stock price has collected 4.33% of gains in the last five trading ...See details»


Client Profile: Novartis AG

Source from : OpenSecrets.org - 18 days ago

Filter by Former Members of Congress: All Non Former Members of Congress Novartis Corp $1,300,000 Taylor Booth Revolving Door Profiles Non Former Members of Congress Novartis Corp $1,300,000 Nora ...See details»


Novartis (NYSE:NVS) Price Target Raised to CHF 88 at UBS Group

Source from : ETF Daily News - 1 month ago

About Novartis (Get Rating) Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz.See details»


Novartis Pharma AG: Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

Source from : Finanznachrichten - 16 days ago

and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»


Novartis suspends delivery of cancer treatment as it address potential production issues

Source from : Morningstar%2c Inc. - 23 days ago

The U.S.-listed shares of Novartis AG (NOVN.EB) fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was "temporarily" suspending delivery of its cancer ...See details»


Novartis AG - Stock Quote NOT

Source from : Morningstar%2c Inc. - 23 days ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»


'Please pay attention': Scientist flagged heart-pill toxins early on

Source from : The Straits Times - 20 days ago

When Novartis AG detected NDMA in valsartan ingredients it bought from Huahai during routine testing in June 2018, the potential for the drug to become contaminated during manufacturing wasn't ...See details»


Immune Checkpoint Inhibitors Market is Expected to Incredible Growth 2022-2032 | AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG

Source from : xaralite.com - 5 days ago

According to the report by insightSLICE, titled, โ€œImmune Checkpoint Inhibitors market: Global Market Share, Trends, Analysis and Forecasts 2022 โ€“ 2032โ€. The report provides a detailed analysis of ...See details»


europe-pharmaceutical-drugs-market-will-generate-new-growth-opportunities-2022-2028-glaxosmithkline-plc-astrazeneca-plc-baxter-ag-novartis-ag-image

Europe Pharmaceutical Drugs Market will generate new growth opportunities 2022-2028 | GlaxoSmithKline Plc., AstraZeneca Plc., Baxter AG, Novartis AG,

Source from : Digital Journal - 4 days ago

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of ...See details»


Skin Cancer Drugs Market will have a Rapid Extension During 2022-2028 โ€“ Bristol Myers Squibb, Meda, Novartis AG, Eli Lilly and Pfizer

Source from : xaralite.com - 7 days ago

The Skin Cancer Drugs research examines the current and future condition of the industry, as well as new industry growth efforts. The global environment, market dynamics and factors, penetration ...See details»